Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG: 1099), have jointly introduced the first value-based payment (VBP) plan for lymphoma associated with Fosun Kite’s chimeric antigen receptor (CAR) T cell therapy, Yescarta (axicabtagene ciloleucel). Under this innovative plan, eligible patients who do not achieve complete remission (CR) following Yescarta treatment may receive a refund of up to RMB 600,000 (approximately USD 84,297).
The VBP plan is anchored in the 2014 Lugano Evaluation standards. Fosun Kite will work alongside government bodies and medical institutions—including clinical experts, the National Health Commission, and treatment demonstration centers—to develop criteria for assessing whether a ‘cure’ has been attained.
Yescarta received regulatory approval in the US and Europe for lymphoma treatment in October 2017 and August 2018, respectively, and gained conditional approval in China in June 2021 for treating relapsed or refractory large B-cell lymphoma in adults after second-line or subsequent systemic therapies. In June 2023, the therapy was further approved in China for large B-cell lymphoma (LBCL) that is resistant to first-line immunochemotherapy or has relapsed within 12 months of such treatment.- Flcube.com
